SABCS: Subgroup analysis of trastuzumab deruxtecan shows ‘encouraging’ results in controlling stable brain metastases in HER2-positive metastatic breast cancer
EMBARGOED TIPSHEET SABCS: Subgroup analysis of trastuzumab deruxtecan (T-DXd) shows ‘encouraging’ results in controlling stable brain metastases in HER2-positive metastatic ...